NOWELL P T, SCOTT C A, WILSON A
Br J Pharmacol Chemother. 1962 Jun;18(3):617-24. doi: 10.1111/j.1476-5381.1962.tb01181.x.
A method has been described for the estimation of neostigmine and pyridostigmine in urine by ion exchange treatment and colorimetric estimation of the blue complex produced when either of the drugs is made to react with bromophenol blue. Urine containing 2 mug/ml. or more of neostigmine or 3 mug/ml. or more of pyridostigmine can be quantitatively estimated. After intramuscular injection of neostigmine to patients with myasthenia gravis, up to 67% of the drug is excreted, whilst after oral administration less than 5% is excreted. When pyridostigmine is given by mouth, the amount of drug excreted in the urine varies between approximately 2 and 16%. It has been established by chromatographic analysis that the blue complexes formed under these conditions are due only to neostigmine and pyridostigmine respectively and that the quantitative estimation described is a true measure of the amount of these drugs excreted in the urine. The significance of these results is discussed in relation to the absorption and metabolism of the two drugs.
本文描述了一种通过离子交换处理和比色法来估算尿液中新斯的明和吡啶斯的明含量的方法。当这两种药物中的任何一种与溴酚蓝反应时，会产生蓝色复合物，通过比色法对该复合物进行估算。尿液中新斯的明含量达到2微克/毫升或更高，或吡啶斯的明含量达到3微克/毫升或更高时，即可进行定量估算。对重症肌无力患者肌肉注射新斯的明后，高达67%的药物会被排出，而口服给药后，排出量不到5%。口服吡啶斯的明时，尿液中排出的药物量约在2%至16%之间。色谱分析已证实，在这些条件下形成的蓝色复合物仅分别由新斯的明和吡啶斯的明产生，并且所描述的定量估算真实反映了尿液中这些药物的排出量。结合这两种药物的吸收和代谢情况，对这些结果的意义进行了讨论。
